DSIP (Emideltide) Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
By Evergreen Editorial · 7/25/2026
Medically reviewed by Dr. Casey Greene, PharmD, FMCP, Senior Director of Clinical Informatics
DSIP (Emideltide) Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
Is DSIP legal to compound right now?
No. Compounding DSIP is not currently legal or authorized, and here's exactly where things stand. On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending DSIP, also known by its INN Emideltide, for inclusion on the list of bulk drug substances licensed pharmacies can legally compound. The committee reviewed DSIP for chronic insomnia and opioid withdrawal. Unlike the four peptides reviewed the day before, this vote did not favor inclusion. Evergreen Telehealth will update this page if that changes.
CURRENT REGULATORY STATUS — Last updated: July 24, 2026 On July 24, 2026, PCAC voted 6-7, with one abstention, against recommending DSIP (Emideltide) for inclusion on the FDA's Section 503A Bulks List. Compounding DSIP is not currently authorized under Section 503A, and this vote does not open a path toward that changing based on this nomination.
What is DSIP?
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide first studied in the late 1970s. The FDA refers to it by the international nonproprietary name Emideltide. The FDA's Pharmacy Compounding Advisory Committee reviewed DSIP specifically for chronic insomnia and opioid withdrawal.
Human research on DSIP dates back further than most peptides reviewed this cycle, but the available studies used intravenous administration, not the subcutaneous route most commonly proposed for compounding. Results across those studies were also inconsistent, with some showing improved sleep and others showing no benefit over placebo. This page describes the peptide's regulatory status. It does not make claims about safety or effectiveness beyond what the FDA committee reviewed.
| Question | Answer |
|---|---|
| Did PCAC vote to recommend DSIP? | No. On July 24, 2026, the committee voted 6-7, with one abstention, against recommending DSIP for inclusion. |
| Is DSIP legal to compound today? | No. |
| Has the FDA approved DSIP as a drug? | No. DSIP has never been FDA-approved for any use, and this vote does not change that. |
| Does a negative vote ban DSIP? | No. DSIP was already outside the legal 503A compounding framework before this vote. A negative recommendation does not add a new restriction. It simply means no new pathway opened. |
What happens next?
A negative PCAC vote does not start FDA rulemaking. The nomination reviewed at this meeting does not move forward toward a proposed rule based on this outcome. DSIP stays outside the 503A Bulks List for the reviewed uses. If DSIP is renominated in the future and later recommended for inclusion, the FDA would use the same legal mechanism described on the other peptide status pages: Section 503A of the FD&C Act together with FDA's general rulemaking authority under section 701(a) (21 U.S.C. 371(a)), a Notice of Proposed Rulemaking under 21 CFR 216.23, a public comment period typically 60 to 90 days, and a final rule that typically takes effect 30 days after publication. None of that is active for DSIP today.
| Stage | Status as of July 24, 2026 |
|---|---|
| PCAC advisory vote | Complete. Voted 6-7, one abstention, against recommending inclusion. |
| FDA rulemaking based on this nomination | Not proceeding, as a direct result of the negative vote. |
| Legal compounding under Section 503A | Not currently authorized, and no active process is underway to change that for DSIP as reviewed at this meeting. |
How do I access DSIP through a licensed pharmacy?
You cannot legally access compounded DSIP through any licensed 503A pharmacy today, and this vote does not create a near-term path to that changing. Evergreen Telehealth does not compound, dispense, or facilitate access to DSIP.
| Access path | Legal status today | Practitioner and quality oversight |
|---|---|---|
| Licensed 503A compounding pharmacy | Not available. No active rulemaking process is underway for DSIP following this vote. | Physician evaluation, licensed pharmacist compounding, fulfillment through top 1% national PCAB/ASHP-accredited partner pharmacies, when and if a legal pathway exists |
| Unregulated online "research chemical" sellers | Outside the legal compounding framework, unaffected by this vote in either direction | No standardized purity testing, no prescription requirement, no pharmacist oversight |
PCAB/ASHP-accredited facility standards reflect Evergreen's own partner-pharmacy requirement. They are not a mandatory condition of any FDA final rule, if and when one is issued.
Common questions about DSIP right now
Does this mean DSIP is now banned? No. DSIP was already outside the legal compounding framework before this vote. Nothing about its legal status became more restrictive. It simply means the committee did not recommend opening a new legal pathway for it.
Why did DSIP get a different outcome than BPC-157, KPV, TB-500, and MOTS-c? The committee reviewed each peptide on its own evidence. For DSIP, the available human research used a different method of administration than the one proposed for compounding, and the results across studies were inconsistent. The committee weighed that evidence differently than it did for the other four.
Can I still buy DSIP online today? You can find it sold online as a "research chemical," but that market sits outside the licensed pharmacy system. It carries no standardized purity testing, no prescription requirement, and no pharmacist oversight. This vote does not change that either way.
Will my doctor be able to prescribe compounded DSIP soon? Not based on this review. This nomination does not proceed toward FDA rulemaking. A new pathway would require a separate future nomination and review.
How will I know if this changes? We will keep this page updated if anything changes. Check the status box at the top of this page any time for the most current information.
Medically reviewed by Dr. Casey Greene, PharmD, FMCP, Director of Consultative Services, Evergreen Telehealth, on July 24, 2026.
Regulatory disclosures
This page describes a regulatory process. It is not medical advice. It does not claim that DSIP is safe or effective for any use. It does not claim or imply FDA approval or disapproval of DSIP beyond describing this committee's recommendation. This page will be updated if anything about this status changes.